Drug Profile
Research programme: hepatitis C therapy - Roche
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 01 Nov 2004 Preclinical trials in Hepatitis C (unspecified route)